[Protective effect of (-) clausenamide against neurotoxicity induced by okadaic acid and beta-amyloid peptide25-35].
This study is to investigate the protective effect of (-) clausenamide against the neurotoxicity of okadaic acid in SH-SY5Y cell line, and injection beta-amyloid peptide25-35 (Abeta25-35) to the cerebral ventricle in ovariectomy (OVX) rats. MTT assay, LDH assay, and Hoechst 33258 staining were used to detect the effect of (-) clausenamide on the toxicity of okadaic acid in SH-SY5Y cell line. The animal model was induced by ovariectomized and injection of Abeta25-35 in the cerebroventricle of rats. The effect of (-) clausenamide on learning and memory deficiency was observed by step-through test. Electron microscope, Nissl body staining, and HE staining were used to examine the morphological changes in hippocampus and cerebral cortex neurons. Pretreatment of (-) clausenamide and LiCl decreased the rate of cell death from MTT, LDH release, and apoptosis from Hoechst 33258 staining in SH-SY5Y cell line. The step-through tests showed (-) clausenamide could improve the ability of learning and memory. The Nissl body staining and HE staining experiments also showed the neuroprotective effects of (-) clausenamide on the neurons of hippocampus and cerebral cortex. (-) Clausenamide has the protective effects against the neurotoxicity induced by okadaic acid and Abeta25-35.
Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Jing
J
Zhang
Yong
Y
Cheng
Jun-Tian
JT
Zhang
D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors / Q000633:toxicity; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002540:Cerebral Cortex / Q000166:cytology; D054700:Clausena / Q000737:chemistry; D004365:Drugs, Chinese Herbal / Q000302:isolation & purification / Q000494:pharmacology; D005260:Female; D006624:Hippocampus / Q000166:cytology; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D007769:Lactams / Q000302:isolation & purification / Q000494:pharmacology*; D007858:Learning / Q000187:drug effects*; D017705:Lignans / Q000302:isolation & purification / Q000494:pharmacology*; D008569:Memory Disorders / Q000503:physiopathology; D009447:Neuroblastoma / Q000378:metabolism / Q000473:pathology*; D009474:Neurons / Q000187:drug effects; D018696:Neuroprotective Agents / Q000302:isolation & purification / Q000494:pharmacology*; D019319:Okadaic Acid / Q000037:antagonists & inhibitors / Q000633:toxicity; D010052:Ovariectomy; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000633:toxicity; D010946:Plants, Medicinal / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley
D016229:Amyloid beta-Peptides; D004365:Drugs, Chinese Herbal; D007769:Lactams; D017705:Lignans; D018696:Neuroprotective Agents; D010446:Peptide Fragments; C074636:amyloid beta-protein (25-35); C053048:clausenamide; D019319:Okadaic Acid; D007770:L-Lactate Dehydrogenase